ClinicalTrials.gg
Not yet recruitingNCT07656441Updated Jun 18, 2026

Mobilization With Movement in Rotator Cuff Tendinopathy

An interventional study of Exercise Therapy and Mobilization With Movement (MWM) in Rotator Cuff Syndrome, sponsored by Kirsehir Ahi Evran Universitesi. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Kirsehir Ahi Evran Universitesi · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This randomized controlled trial aims to investigate the effects of Mobilization With Movement (MWM) combined with exercise therapy on tendon morphology, pain, and functional outcomes in individuals with rotator cuff tendinopathy. A total of approximately 60 participants diagnosed with supraspinatus tendinopathy will be randomly assigned to either an exercise-only group or an exercise plus MWM group.

All participants will undergo a standardized rehabilitation program for 8 weeks. Clinical outcomes, including pain intensity (Visual Analog Scale), shoulder function (SPADI and QuickDASH), range of motion, muscle strength, proprioception, and psychosocial status (Tampa Scale of Kinesiophobia, Pain Catastrophizing Scale, and Central Sensitization Inventory), will be assessed at baseline and post-intervention. In addition, ultrasound imaging will be used to evaluate tendon morphology, including tendon thickness, subacromial bursa thickness, acromiohumeral distance, echogenicity, and vascularity.

The primary objective is to determine whether MWM produces superior improvements in clinical outcomes and whether it is associated with measurable changes in tendon structure as assessed by ultrasound. The findings are expected to contribute to a better understanding of the biomechanical and neurophysiological mechanisms underlying manual therapy in rotator cuff tendinopathy and to provide evidence for its role in musculoskeletal rehabilitation.

Read the detailed description

Rotator cuff tendinopathy is one of the most common causes of shoulder pain and functional limitation, often resulting in reduced quality of life and impaired upper extremity performance. Although exercise therapy is widely accepted as the cornerstone of conservative management, the additional benefit of manual therapy techniques, particularly Mobilization With Movement (MWM), remains an area of ongoing investigation. Furthermore, the potential effects of manual therapy on tendon morphology assessed via ultrasound imaging are not yet fully understood.

This randomized controlled trial will examine whether the addition of MWM to a standardized exercise program provides superior outcomes compared to exercise alone in individuals with supraspinatus tendinopathy. Participants will be randomly allocated into two groups: an exercise-only group and an exercise plus MWM group. Both interventions will be delivered over an 8-week period.

The study will focus on both clinical and imaging-based outcomes. Clinical outcomes include pain intensity, shoulder function, range of motion, muscle strength, proprioception, and psychosocial factors such as fear of movement, pain catastrophizing, and central sensitization. Imaging outcomes will be assessed using musculoskeletal ultrasound to evaluate tendon thickness, subacromial bursa thickness, acromiohumeral distance, echogenicity, and vascularity.

The primary aim is to determine whether MWM induces superior improvements in pain and function and whether these changes are accompanied by measurable alterations in tendon morphology. Secondary aims include exploring the relationship between ultrasound-based structural changes and clinical outcomes, as well as evaluating the potential role of psychosocial factors in treatment response.

This study is expected to provide new evidence regarding the structural and functional effects of manual therapy in rotator cuff tendinopathy and to clarify whether improvements in clinical symptoms are associated with objective changes in tendon morphology.

02

Conditions studied

  • Rotator Cuff Syndrome
03

In context

Lead sponsor

Kirsehir Ahi Evran Universitesi is the lead sponsor of 138 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years
  • Clinical diagnosis of rotator cuff tendinopathy (supraspinatus involvement) confirmed by musculoskeletal ultrasound
  • Shoulder pain duration of at least 3 months
  • Pain intensity ≥ 3/10 on the Visual Analog Scale (VAS)
  • Ability to understand and follow instructions and complete questionnaires

Exclusion criteria

Exclusion Criteria:

  • Full-thickness or large rotator cuff tear confirmed by ultrasound or MRI
  • History of shoulder surgery on the affected side
  • Diagnosis of adhesive capsulitis (frozen shoulder)
  • Shoulder instability or dislocation history
  • Cervical radiculopathy or referred neck-related shoulder pain
  • Inflammatory rheumatic diseases (e.g., rheumatoid arthritis, ankylosing spondylitis)
  • Neurological disorders affecting upper extremity function
  • injection in the shoulder within the last 6 months
  • Ongoing physiotherapy or manual therapy treatment for shoulder pain in the last 3 months
  • Severe systemic or psychiatric conditions that may interfere with participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Exercise Only Group

    Participants will receive a standardized shoulder exercise program focusing on rotator cuff strengthening, scapular stabilization, stretching, and range of motion exercises.

    Behavioral: Exercise Therapy

  • Experimental
    Exercise + Mobilization With Movement (MWM) Group

    Participants will receive the same standardized exercise program in addition to glenohumeral joint Mobilization With Movement (MWM) techniques.

    Behavioral: Exercise Therapy · Procedure: Mobilization With Movement (MWM)

Interventions

  • BehavioralExercise Therapy

    A standardized physiotherapy program including rotator cuff strengthening exercises, scapular stabilization exercises, posterior capsule stretching, pectoralis minor stretching, and active range of motion exercises for the shoulder.3 sessions per week for 8 weeks (supervised and/or home-based depending on protocol design)

  • ProcedureMobilization With Movement (MWM)

    Glenohumeral joint Mobilization With Movement techniques (Mulligan concept), including posterior glide and inferior glide techniques applied during active shoulder movement, aimed at improving pain-free range of motion and function. Application Details: Grade: Sustained glide during active movement Techniques: Posterior glide, inferior glide Dosage: 2 sessions per week for 8 weeks Performed by licensed physiotherapist

06

What researchers measure

Primary outcomes

  1. Supraspinatus Tendon Thickness

    Supraspinatus tendon thickness will be measured using musculoskeletal ultrasound imaging. Measurements will be obtained at the tendon footprint in the longitudinal plane using a high-frequency linear transducer. Tendon thickness will be recorded in millimeters (mm). This variable is selected as the primary structural outcome to evaluate morphological changes associated with the intervention. Increased or decreased tendon thickness will be interpreted in relation to clinical improvement and tissue remodeling.

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

Secondary outcomes

  1. Pain Intensity

    Pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS). Participants will rate their pain at rest, during activity, and at night. Scores range from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

  2. Shoulder Pain and Disability Index (SPADI)

    SPADI will be used to evaluate shoulder pain and functional disability. The questionnaire consists of pain and disability subscales, with total scores ranging from 0 to 100. Higher scores indicate greater disability.

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

  3. QuickDASH Score

    QuickDASH will assess upper limb disability and symptoms. It consists of 11 items scored from 1 to 5, converted to a scale from 0 to 100. Higher scores indicate greater functional limitation.

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

  4. Shoulder Range of Motion (ROM)

    Active shoulder flexion, abduction, internal rotation, and external rotation will be measured using a goniometer or digital inclinometer in degrees.

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

  5. Shoulder Muscle Strength

    Isometric muscle strength of shoulder abductors and external rotators will be measured using a handheld dynamometer. Results will be recorded in Newtons (N).

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

  6. Joint Position Sense (JPS)

    Shoulder proprioception will be assessed using a laser pointer method. The participant will attempt to reproduce a target shoulder flexion position with eyes closed. Deviation from the target position will be recorded in centimeters. Higher values indicate poorer proprioception.

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

  7. Tampa Scale of Kinesiophobia (TSK)

    TSK will be used to assess fear of movement and reinjury. The scale consists of 17 items scored on a 4-point Likert scale. Total scores range from 17 to 68, with higher scores indicating greater fear of movement.

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

  8. Pain Catastrophizing Scale (PCS)

    PCS measures exaggerated negative cognitive responses to pain, including rumination, magnification, and helplessness. It consists of 13 items with a total score ranging from 0 to 52. Higher scores indicate greater catastrophizing.

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

  9. Central Sensitization Inventory (CSI)

    CSI is a 25-item questionnaire assessing symptoms related to central sensitization. Total scores range from 0 to 100, with higher scores indicating greater central sensitization-related symptom severity.

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07656441
Responsible party
Ömer Faruk ÖZÇELEP (Assist. Prof., Kirsehir Ahi Evran Universitesi) — Principal investigator
First posted
Jun 18, 2026
Start date
Jul 8, 2026 (estimated)
Primary completion
Dec 12, 2026 (estimated)
Completion
Dec 13, 2026 (estimated)
Last update
Jun 18, 2026

Study contacts

Ömer ÖZÇELEP, Assist. Prof.
study director · Kirsehir Ahi Evran Universitesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion